Rockwell Medical (NasdaqGM: RMTI) is an established commercial biopharmaceutical company offering innovative products and services for hemodialysis. The Company received FDA approval on January 26th for Triferic, the only treatment indicated to replace iron and maintain hemoglobin in hemodialysis patients. Triferic has the potential to transform iron management in dialysis, and is especially well positioned in the bundled payment system. Rockwell has an established core business selling dialysis concentrates in partnership with Baxter (NYSE: BAX). Triferic and a generic vitamin D supplement for dialysis, Calcitriol, are expected to launch in the summer of 2015.